Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management - Scorecard - MDSpire
Advertisement
Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management
Clinical Scorecard: Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management
At a Glance
Category
Detail
Condition
Key Mechanisms
Control of inflammation through immunomodulators, biologics, and 5-aminosalicylates, with implications for cardiovascular risk.
Target Population
Care Setting
Key Highlights
IBD affects approximately 3 million people in the US.
5-ASAs are first-line therapy for mild to moderate colonic inflammation.
Biologics are standard care for moderate to severe IBD.
IBD is associated with increased cardiovascular disease risk, including specific statistics.
Older adults with IBD face higher risks of major adverse cardiovascular events.
Guideline-Based Recommendations
Diagnosis
Management
Initiate 5-ASAs for mild to moderate IBD; consider biologics for moderate to severe cases.
Include monitoring strategies for older adults.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Immunomodulators and biologics may mitigate cardiovascular risks but have mixed evidence regarding their effects on MACE; clarify this point.
Clinical Best Practices
Consider patient age and comorbidities when prescribing immunomodulators or biologics, with a focus on their impact on treatment decisions.
Evaluate the risk-benefit ratio of treatment options in older adults with IBD.
